Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer

Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheon, Yun-Hong, Kim, Moon Jin, Kang, Min Gyu, Kim, Hee Jin, Lee, Sang Su, Kim, Cha Young, Jeon, Dae-Hong, Kim, Yu Eun, Lee, Gyeong-Won
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104451/
https://www.ncbi.nlm.nih.gov/pubmed/21623617
http://dx.doi.org/10.3349/ymj.2011.52.4.695
_version_ 1782204604622045184
author Cheon, Yun-Hong
Kim, Moon Jin
Kang, Min Gyu
Kim, Hee Jin
Lee, Sang Su
Kim, Cha Young
Jeon, Dae-Hong
Kim, Yu Eun
Lee, Gyeong-Won
author_facet Cheon, Yun-Hong
Kim, Moon Jin
Kang, Min Gyu
Kim, Hee Jin
Lee, Sang Su
Kim, Cha Young
Jeon, Dae-Hong
Kim, Yu Eun
Lee, Gyeong-Won
author_sort Cheon, Yun-Hong
collection PubMed
description Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
format Text
id pubmed-3104451
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-31044512011-07-01 Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer Cheon, Yun-Hong Kim, Moon Jin Kang, Min Gyu Kim, Hee Jin Lee, Sang Su Kim, Cha Young Jeon, Dae-Hong Kim, Yu Eun Lee, Gyeong-Won Yonsei Med J Case Report Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy. Yonsei University College of Medicine 2011-07-01 2011-05-21 /pmc/articles/PMC3104451/ /pubmed/21623617 http://dx.doi.org/10.3349/ymj.2011.52.4.695 Text en © Copyright: Yonsei University College of Medicine 2011 http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Cheon, Yun-Hong
Kim, Moon Jin
Kang, Min Gyu
Kim, Hee Jin
Lee, Sang Su
Kim, Cha Young
Jeon, Dae-Hong
Kim, Yu Eun
Lee, Gyeong-Won
Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
title Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
title_full Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
title_fullStr Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
title_full_unstemmed Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
title_short Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
title_sort bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104451/
https://www.ncbi.nlm.nih.gov/pubmed/21623617
http://dx.doi.org/10.3349/ymj.2011.52.4.695
work_keys_str_mv AT cheonyunhong bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT kimmoonjin bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT kangmingyu bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT kimheejin bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT leesangsu bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT kimchayoung bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT jeondaehong bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT kimyueun bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer
AT leegyeongwon bowelperforationaftererlotinibtreatmentinapatientwithnonsmallcelllungcancer

Ejemplares similares